iclepertin

News

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.